| Title : Intranasal administration of acetylcholinesterase inhibitors - Costantino_2008_BMC.Neurosci_9 Suppl 3_S6 |
| Author(s) : Costantino HR , Leonard AK , Brandt G , Johnson PH , Quay SC |
| Ref : BMC Neurosci , 9 Suppl 3 :S6 , 2008 |
|
Abstract :
This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeutically viable formulation. In vivo testing confirmed achievement of therapeutically relevant drug levels that matched or exceeded those for oral dosing, with a dramatic reduction in undesired emetic responses. Intranasal drug delivery is an effective option for the treatment of Alzheimer's disease and other central nervous system disorders. |
| PubMedSearch : Costantino_2008_BMC.Neurosci_9 Suppl 3_S6 |
| PubMedID: 19091003 |
Costantino HR, Leonard AK, Brandt G, Johnson PH, Quay SC (2008)
Intranasal administration of acetylcholinesterase inhibitors
BMC Neurosci
9 Suppl 3 :S6
Costantino HR, Leonard AK, Brandt G, Johnson PH, Quay SC (2008)
BMC Neurosci
9 Suppl 3 :S6